Clinical trials: Age Related Maculopathy
Macular Edema
Treatment of CNV With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3
To determine whether a combination of intravitreal aflibercept and pranoprofen eyedrops or nutraceutical support provides additional benefit over IVA monotherapy for the treatment of choroidal neovascularization in age-related…
- Trial name
- NCT03355638
- Testing
- Aflibercept Injection [Eylea], Pranoprofen Eyedrops, Omega-3 Supplementation
- Volunteers
- 60 people
- Sponsor
- Università degli Studi di Brescia
Age-Related Macular Degeneration
Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression
This randomized, double-blind, placebo-controlled study aims to evaluate the effect of krill oil supplementation in patients with dry age-related macular degeneration (AMD).
- Trial name
- OMEGA-AMD (NCT05465252)
- Testing
- Krill Oil, Olive Oil
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Age-Related (Dry) Macular Degeneration
Transpalpebral Micro-Current Electrical Stimulation for the Treatment of Dry Age-Related Macular Degeneration
Assess the effectiveness of externally applied micro current electrical stimulation on improving the ETDRS visual acuity in subjects with vision loss from dry age-related macular degeneration (AMD)
- Trial name
- NCT02540148
- Testing
- Nova Oculus™ Micro-current electrical stimulation
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- The Eye Machine Canada Inc.
Macular Degeneration
VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)
This study will assess the efficacy and safety of intravitreally (IVT), i.e. directly into the eye administered VEGF Trap-Eye compared with photodynamic therapy (PDT) on visual function in Chinese subjects with age-related…
- Trial name
- NCT01482910
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321), Visudyne
- Where
- 14 sites in China
- Volunteers
- 304 people
- Sponsor
- Bayer
Choroidal Neovascularization, Macular Degeneration
Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)
The objective of this study is to determine if combination therapy (reduced-fluence Visudyne followed by Lucentis [within 2 hours] or either of two regimens of reduced-fluence Visudyne followed by Lucentis-Dexamethasone triple…
- Trial name
- RADICAL (NCT00492284)
- Testing
- verteporfin, ranibizumab, dexamethasone
- Where
- 26 sites in United States, Canada
- Volunteers
- 162 people
- Sponsor
- QLT Inc.
Geographic Atrophy
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD).
- Trial name
- ArMaDa (NCT06018558)
- Testing
- OCU410
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ocugen
Age-related Macular Degeneration, Cataract
Age-Related Eye Disease Study 2 (AREDS2)
Oral supplementation with the Age-Related Eye Disease Study (AREDS) formulation (antioxidant vitamins C and E, beta carotene, and zinc) has been shown to reduce the risk of progression to advanced age-related macular degeneration…
- Trial name
- AREDS2 (NCT00345176)
- Testing
- Lutein/zeaxanthin, DHA/EPA, Lutein/zeaxanthin and DHA/EPA
- Where
- 91 sites in United States
- Volunteers
- 4,203 people
- Sponsor
- National Eye Institute (NEI)
Wet Age Related Macular Degeneration, wAMD
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
- Trial name
- wAMD (NCT06668064)
- Testing
- EYP-1901, Aflibercept (2.0 mg)
- Where
- 76 sites in United States
- Volunteers
- 400 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Age-Related Macular Degeneration
Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)
In this prospective, open-label clinical study is to investigate the behavior of the retinal functions during development of diabetic macular disease (DME) under the influence of Lucentis.
- Trial name
- NCT01638858
- Testing
- Lucentis (Ranibizumab)
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- University of Luebeck
Neovascular Age-related Macular Degeneration
Defining Disease Activity in Neovascular AMD With Optical Coherence Tomography Angiography
The purpose of this study is to be able to describe optical coherence angiography (OCTA) patterns of disease activity and quiescence in eyes that have received treatment.
- Trial name
- DANA (NCT03909425)
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Neovascular Age-related Macular Degeneration
Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.
This is a prospective, multicenter, single arm study. The study group will be compose of NVAMD patients who had partial or complete failure responding to initial bevacizumab or ranibizumab treatment of 3-6 monthly intravitreal…
- Trial name
- NCT01918878
- Testing
- Aflibercept (EYLEA)
- Where
- Israel
- Volunteers
- 48 people
- Sponsor
- Hadassah Medical Organization
Age Related Macular Degeneration
Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)
The purpose of this first in man study is to examine the safety of an experimental gene transfer agent, RetinoStat, designed to treat neovascular age-related macular degeneration.
- Trial name
- GEM (NCT01301443)
- Testing
- Subretinally injected RetinoStat
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Oxford BioMedica
Macular Degeneration
Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60
This study will explore whether taking the vitamins lutein and zeaxanthin, with or without Omega-3 fatty acid (fish oil or docosahexanoic acid, also known as DHA) will change the amount of lutein and zeaxanthin in the blood among…
- Trial name
- NCT00121589
- Testing
- Lutein
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Age Related Macular Degeneration
PHP Home Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization (CNV)
The primary objective of this study is to assess the ability of the PHP \& HPHP to detect newly diagnosed non treated Chorodial neovascularization (CNV) lesion associate with advanced age related Macular Degeneration (AMD) and…
- Trial name
- NCT00359008
- Where
- Israel
- Volunteers
- 336 people
- Sponsor
- Notal Vision Ltd.
Age Related Macular Degeneration
Intravitreal Bevacizumab for Age-Related Macular Degeneration
The purpose of this study is to determine whether intravitreal injection of bevacizumab is effective in the treatment of neovascular age related macular degeneration
- Trial name
- NCT00347165
- Testing
- bevacizumab intravitreal injection
- Where
- Mexico
- Volunteers
- 50 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Age Related Macular Degeneration
WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination
The purpose of this study is to evaluate the safety, tolerability, and effects of investigational drug AL-39324 for the treatment of wet AMD.
- Trial name
- NCT00992563
- Testing
- AL-39324 ophthalmic suspension, Ranibizumab 10 mg/mL
- Volunteers
- 35 people
- Sponsor
- Alcon Research
Age-Related Macular Degeneration, Macular Degeneration, Age-Related
Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD
The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients…
- Conditions
- Age-Related Macular Degeneration, Macular Degeneration, Age-Related, Dry Macular Degeneration, Geographic Atrophy
- Trial name
- METforMIN (NCT02684578)
- Testing
- Metformin
- Where
- 12 sites in United States
- Volunteers
- 66 people
- Sponsor
- University of California, San Francisco
Macular Degeneration, Age-Related, Geographic Atrophy
A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
The purpose of this study is to evaluate the long-term safety and tolerability of intravitreal (ITV) injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 weeks (Q8W) in participants with geographic…
- Trial name
- NCT04607148
- Testing
- Galegenimab
- Where
- 48 sites in United States
- Volunteers
- 144 people
- Sponsor
- Genentech, Inc.
Wet Age-related Macular Degeneration
First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)
Phase 1 open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of a single dose injections of EYP-1901 at three dose levels: 440 µg, 2060 µg and 3090 µg in subjects with Wet Age…
- Trial name
- NCT04747197
- Testing
- EYP-1901
- Where
- 11 sites in United States
- Volunteers
- 17 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Neovascular (Wet) Age-related Macular Degeneration (AMD)
A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]
The purpose of this study is to compare the efficacy and safety of ABP 938 versus Aflibercept (Eylea®) in the treatment of neovascular age-related macular degeneration.
- Trial name
- NCT04270747
- Testing
- ABP 938, Aflibercept
- Where
- 118 sites in United States, Canada and 16 more
- Volunteers
- 576 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.